Preventing progression of allergic rhinitis: The role of specific immunotherapy

Alessandro Fiocchi, Adam T. Fox

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Allergic rhinitis and asthma are examples of allergic airways disease. Despite their differing symptomatology, both disorders affect the mucosal lining of the respiratory tract and are linked by common underlying cellular processes, thus, using the 'united airways' approach, they can be considered part of the same allergic disease. The conditions are often comorbid, and there is evidence to suggest that allergic rhinitis in children is a significant risk factor for subsequent development of asthma. Management strategies that target the underlying cause of allergic rhinitis in children have the potential to offer additional symptom control above that of symptomatic medications, and prevent disease progression. Specific immunotherapy (SIT) is the only currently available treatment that is proven to target the disease in this way. SIT affects the underlying cause of allergic rhinitis, producing changes in antibody responses to allergens. It has been shown to be effective in the reduction of allergic rhinitis symptoms in both children and adults, with effects being sustained for several years after treatment completion. Furthermore, a number of trials provide evidence that SIT may prevent the development of new sensitisations and asthma in children and adults with allergic rhinitis. One such open-label, randomised controlled study in children/adolescents (the Preventive Allergy Treatment Study) showed that significantly fewer patients who received 3 years of SIT for grass/ birch pollen-induced allergic rhinitis had developed asthma 10 years after treatment initiation versus controls. Some clinical guidelines acknowledge this potential asthma preventive effect in children and the need for additional data from double-blind, placebo-controlled trials to support these findings.

Original languageEnglish
Pages (from-to)91-100
Number of pages10
JournalArchives of Disease in Childhood: Education and Practice Edition
Volume96
Issue number3
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Immunotherapy
Asthma
Betula
Therapeutics
Pollen
Poaceae
Allergic Rhinitis
Respiratory System
Allergens
Antibody Formation
Disease Progression
Hypersensitivity
Placebos
Guidelines

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Preventing progression of allergic rhinitis : The role of specific immunotherapy. / Fiocchi, Alessandro; Fox, Adam T.

In: Archives of Disease in Childhood: Education and Practice Edition, Vol. 96, No. 3, 06.2011, p. 91-100.

Research output: Contribution to journalArticle

@article{7dd7ac9874df40d6be614a2d9c5ec167,
title = "Preventing progression of allergic rhinitis: The role of specific immunotherapy",
abstract = "Allergic rhinitis and asthma are examples of allergic airways disease. Despite their differing symptomatology, both disorders affect the mucosal lining of the respiratory tract and are linked by common underlying cellular processes, thus, using the 'united airways' approach, they can be considered part of the same allergic disease. The conditions are often comorbid, and there is evidence to suggest that allergic rhinitis in children is a significant risk factor for subsequent development of asthma. Management strategies that target the underlying cause of allergic rhinitis in children have the potential to offer additional symptom control above that of symptomatic medications, and prevent disease progression. Specific immunotherapy (SIT) is the only currently available treatment that is proven to target the disease in this way. SIT affects the underlying cause of allergic rhinitis, producing changes in antibody responses to allergens. It has been shown to be effective in the reduction of allergic rhinitis symptoms in both children and adults, with effects being sustained for several years after treatment completion. Furthermore, a number of trials provide evidence that SIT may prevent the development of new sensitisations and asthma in children and adults with allergic rhinitis. One such open-label, randomised controlled study in children/adolescents (the Preventive Allergy Treatment Study) showed that significantly fewer patients who received 3 years of SIT for grass/ birch pollen-induced allergic rhinitis had developed asthma 10 years after treatment initiation versus controls. Some clinical guidelines acknowledge this potential asthma preventive effect in children and the need for additional data from double-blind, placebo-controlled trials to support these findings.",
author = "Alessandro Fiocchi and Fox, {Adam T.}",
year = "2011",
month = "6",
doi = "10.1136/adc.2010.183095",
language = "English",
volume = "96",
pages = "91--100",
journal = "Archives of Disease in Childhood: Education and Practice Edition",
issn = "1743-0585",
publisher = "BMJ Publishing Group",
number = "3",

}

TY - JOUR

T1 - Preventing progression of allergic rhinitis

T2 - The role of specific immunotherapy

AU - Fiocchi, Alessandro

AU - Fox, Adam T.

PY - 2011/6

Y1 - 2011/6

N2 - Allergic rhinitis and asthma are examples of allergic airways disease. Despite their differing symptomatology, both disorders affect the mucosal lining of the respiratory tract and are linked by common underlying cellular processes, thus, using the 'united airways' approach, they can be considered part of the same allergic disease. The conditions are often comorbid, and there is evidence to suggest that allergic rhinitis in children is a significant risk factor for subsequent development of asthma. Management strategies that target the underlying cause of allergic rhinitis in children have the potential to offer additional symptom control above that of symptomatic medications, and prevent disease progression. Specific immunotherapy (SIT) is the only currently available treatment that is proven to target the disease in this way. SIT affects the underlying cause of allergic rhinitis, producing changes in antibody responses to allergens. It has been shown to be effective in the reduction of allergic rhinitis symptoms in both children and adults, with effects being sustained for several years after treatment completion. Furthermore, a number of trials provide evidence that SIT may prevent the development of new sensitisations and asthma in children and adults with allergic rhinitis. One such open-label, randomised controlled study in children/adolescents (the Preventive Allergy Treatment Study) showed that significantly fewer patients who received 3 years of SIT for grass/ birch pollen-induced allergic rhinitis had developed asthma 10 years after treatment initiation versus controls. Some clinical guidelines acknowledge this potential asthma preventive effect in children and the need for additional data from double-blind, placebo-controlled trials to support these findings.

AB - Allergic rhinitis and asthma are examples of allergic airways disease. Despite their differing symptomatology, both disorders affect the mucosal lining of the respiratory tract and are linked by common underlying cellular processes, thus, using the 'united airways' approach, they can be considered part of the same allergic disease. The conditions are often comorbid, and there is evidence to suggest that allergic rhinitis in children is a significant risk factor for subsequent development of asthma. Management strategies that target the underlying cause of allergic rhinitis in children have the potential to offer additional symptom control above that of symptomatic medications, and prevent disease progression. Specific immunotherapy (SIT) is the only currently available treatment that is proven to target the disease in this way. SIT affects the underlying cause of allergic rhinitis, producing changes in antibody responses to allergens. It has been shown to be effective in the reduction of allergic rhinitis symptoms in both children and adults, with effects being sustained for several years after treatment completion. Furthermore, a number of trials provide evidence that SIT may prevent the development of new sensitisations and asthma in children and adults with allergic rhinitis. One such open-label, randomised controlled study in children/adolescents (the Preventive Allergy Treatment Study) showed that significantly fewer patients who received 3 years of SIT for grass/ birch pollen-induced allergic rhinitis had developed asthma 10 years after treatment initiation versus controls. Some clinical guidelines acknowledge this potential asthma preventive effect in children and the need for additional data from double-blind, placebo-controlled trials to support these findings.

UR - http://www.scopus.com/inward/record.url?scp=79956309567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956309567&partnerID=8YFLogxK

U2 - 10.1136/adc.2010.183095

DO - 10.1136/adc.2010.183095

M3 - Article

C2 - 21047834

AN - SCOPUS:79956309567

VL - 96

SP - 91

EP - 100

JO - Archives of Disease in Childhood: Education and Practice Edition

JF - Archives of Disease in Childhood: Education and Practice Edition

SN - 1743-0585

IS - 3

ER -